Related Experiment Video

Updated: Jun 9, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Drug treatment failures and effectivity in children with newly diagnosed epilepsy

Ebru Arhan1, Ayse Serdaroglu, Ayse Nese Cıtak Kurt

  • 1Department of Pediatric Neurology, Gazi University School of Medicine, Turkey. petekarhan@yahoo.com.tr

Seizure
|August 27, 2010
PubMed

Insights

Approximately one-third of children with new epilepsy diagnoses fail their first antiepileptic drug treatment. Treatment failure in pediatric epilepsy is often due to adverse effects or lack of efficacy.

Area of Science:

  • Pediatric Neurology
  • Epilepsy Treatment
  • Pharmacology

Background:

  • Epilepsy is a common neurological disorder in children.
  • Effective first-line antiepileptic drug (AED) treatment is crucial for seizure control and quality of life.
  • Understanding treatment failure rates and reasons is essential for optimizing pediatric epilepsy management.

Purpose of the Study:

  • To determine the percentage of children experiencing first-line AED treatment failure in newly diagnosed epilepsy.
  • To identify the specific reasons for treatment failure in this pediatric population.

Main Methods:

  • Retrospective review of hospital records for 225 newly diagnosed pediatric epilepsy patients.
  • Monitoring of patients for approximately 4.2 years after initiation of first-line AED therapy.
  • Analysis of seizure types, epilepsy etiology, prescribed AEDs, and reasons for treatment discontinuation.

Main Results:

  • Overall, 67.5% of children achieved successful seizure control with their first AED.
  • Treatment failure occurred in 32.5% of patients (73 out of 225).
  • Reasons for failure were equally attributed to adverse effects (38.3%) and lack of efficacy (35.6%), with a combination in 26.02%.

Conclusions:

  • Nearly one-third of children with newly diagnosed epilepsy do not respond successfully to their initial AED.
  • Both adverse effects and insufficient efficacy are significant contributors to first-line treatment failure in pediatric epilepsy.
  • Further research into predictive factors and alternative therapeutic strategies is warranted.
Abstract

More Related Videos

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...